Isradipine
Isradipine (isradipine) is a small molecule pharmaceutical. Isradipine was first approved as Dynacirc on 1990-12-20. It is used to treat hypertension and variant angina pectoris in the USA. It is known to target voltage-dependent L-type calcium channel subunit alpha-1F, voltage-dependent L-type calcium channel subunit alpha-1D, voltage-dependent L-type calcium channel subunit alpha-1S, and voltage-dependent L-type calcium channel subunit alpha-1C.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Isradipine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DYNACIRC CR | GSK | N-020336 DISCN | 1994-06-01 | 2 products, RLD |
| DYNACIRC | Smithkline Beecham | N-019546 DISCN | 1990-12-20 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| isradipine | ANDA | 2023-11-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypertension | EFO_0000537 | D006973 | I10 |
| variant angina pectoris | — | D000788 | I20.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
16 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | 1 | — | 4 | 5 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 2 | 1 | — | 1 | 4 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 2 | 1 | — | — | — | 2 |
| Depression | D003863 | — | F33.9 | — | 1 | — | — | — | 1 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Tobacco use disorder | D014029 | — | F17 | 1 | — | — | — | — | 1 |
| Cigarette smoking | D000073865 | — | — | 1 | — | — | — | — | 1 |
| Smoking | D012907 | EFO_0004318 | — | 1 | — | — | — | — | 1 |
| Smoking cessation | D016540 | EFO_0004319 | — | 1 | — | — | — | — | 1 |
| Craving | D066249 | — | — | 1 | — | — | — | — | 1 |
| Smoking reduction | D000074264 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | — | — | — | — | — | 1 | 1 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | — | — | 1 | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 1 | 1 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | — | — | 1 | 1 |
| Disease progression | D018450 | — | — | — | — | — | — | 1 | 1 |
| Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | — | — | 1 | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Isradipine |
| INN | isradipine |
| Description | Isradipine is an isopropyl ester, a methyl ester, a dihydropyridine and a benzoxadiazole. |
| Classification | Small molecule |
| Drug class | phenylpyridine vasodilators; tricyclic compounds |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc2nonc12 |
Identifiers
| PDB | — |
| CAS-ID | 75695-93-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1648 |
| ChEBI ID | — |
| PubChem CID | 3784 |
| DrugBank | DB00270 |
| UNII ID | YO1UK1S598 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CACNA1F
CACNA1F
CACNA1D
CACNA1D
CACNA1S
CACNA1S
CACNA1C
CACNA1C
Organism
Homo sapiens
Gene name
CACNA1F
Gene synonyms
CACNAF1
NCBI Gene ID
Protein name
voltage-dependent L-type calcium channel subunit alpha-1F
Protein synonyms
calcium channel, voltage-dependent, L type, alpha 1F subunit, Voltage-gated calcium channel subunit alpha Cav1.4
Uniprot ID
Mouse ortholog
Cacna1f (54652)
voltage-dependent L-type calcium channel subunit alpha-1F (Q9JIS7)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Isradipine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,118 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
317 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use